2021-2023

Dynamics of T-cell Responses Following COVID-19 mRNA Vaccination and Breakthrough Infection in Older Adults. Datwani S, Kalikawe R, Mwimanzi F, Speckmaier S, Liang R, Sang Y, Waterworth R, Yaseen F, Lapointe HR, Barad E, DeMarco ML, Holmes DT, Simons J, Montaner JSG, Romney MG, Brumme ZL, Brockman MA. Pathog Immun. 2023 Nov 17;8(1):117-135. doi: 10.20411/pai.v8i1.613. eCollection 2023.

HIV reservoirs are dominated by genetically younger and clonally enriched proviruses.  Kinloch NN, Shahid A, Dong W, Kirkby D, Jones BR, Beelen CJ, MacMillan D, Lee GQ, Mota TM, Sudderuddin H, Barad E, Harris M, Brumme CJ, Jones RB, Brockman MA, Joy JB, Brumme ZL. mBio. 2023 Dec 19;14(6):e0241723. doi: 10.1128/mbio.02417-23. Epub 2023 Nov 16.

Viral and host mediators of non-suppressible HIV-1 viremia. Mohammadi A, Etemad B, Zhang X, Li Y, Bedwell GJ, Sharaf R, Kittilson A, Melberg M, Crain CR, Traunbauer AK, Wong C, Fajnzylber J, Worrall DP, Rosenthal A, Jordan H, Jilg N, Kaseke C, Giguel F, Lian X, Deo R, Gillespie E, Chishti R, Abrha S, Adams T, Siagian A, Dorazio D, Anderson PL, Deeks SG, Lederman MM, Yawetz S, Kuritzkes DR, Lichterfeld MD, Sieg S, Tsibris A, Carrington M, Brumme ZL, Castillo-Mancilla JR, Engelman AN, Gaiha GD, Li JZ. Nat Med. 2023 Dec;29(12):3212-3223. doi: 10.1038/s41591-023-02611-1. Epub 2023 Nov 13.

Near full-length HIV sequencing in multiple tissues collected postmortem reveals shared clonal expansions across distinct reservoirs during ART. Dufour C, Ruiz MJ, Pagliuzza A, Richard C, Shahid A, Fromentin R, Ponte R, Cattin A, Wiche Salinas TR, Salahuddin S, Sandstrom T, Schinkel SB, Costiniuk CT, Jenabian MA, Ancuta P, Routy JP, Cohen ÉA, Brumme ZL, Power C, Angel JB, Chomont N. Cell Rep. 2023 Sep 26;42(9):113053. doi: 10.1016/j.celrep.2023.113053. Epub 2023 Sep 6.

CDK8 inhibitors antagonize HIV-1 reactivation and promote provirus latency in T cells. Horvath RM, Brumme ZL, Sadowski I. J Virol. 2023 Sep 28;97(9):e0092323. doi: 10.1128/jvi.00923-23. Epub 2023 Sep 6.

Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada.  Costiniuk CT, Singer J, Lee T, Galipeau Y, McCluskie PS, Arnold C, Langlois MA, Needham J, Jenabian MA, Burchell AN, Samji H, Chambers C, Walmsley S, Ostrowski M, Kovacs C, Tan DHS, Harris M, Hull M, Brumme ZL, Lapointe HR, Brockman MA, Margolese S, Mandarino E, Samarani S, Vulesevic B, Lebouché B, Angel JB, Routy JP, Cooper CL, Anis AH; COVAXHIV Study Group. AIDS. 2023 Oct 1;37(12):F25-F35. doi: 10.1097/QAD.0000000000003680. Epub 2023 Aug 2.

Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary. Sanders-Beer BE, Archin NM, Brumme ZL, Busch MP, Deleage C, O'Doherty U, Hughes SH, Jerome KR, Jones RB, Karn J, Kearney MF, Keele BF, Kulpa DA, Laird GM, Li JZ, Lichterfeld MD, Nussenzweig MC, Persaud D, Yukl SA, Siliciano RF, Mellors JW. AIDS Res Hum Retroviruses. 2023 Jun 19. doi: 10.1089/AID.2022.0188.

HIV-1 subtype C Nef-mediated SERINC5 down-regulation significantly contributes to overall Nef activity. Naicker D, Sonela N, Jin SW, Mulaudzi T, Ojwach D, Reddy T, Brockman MA, Brumme ZL, Ndung'u T, Mann JK. Retrovirology. 2023 Mar 31;20(1):3. doi: 10.1186/s12977-023-00618-7.

Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine. Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Burns L, Young L, Leung V, Ennis S, Brumme CJ, Montaner JSG, Dong W, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. Open Forum Infect Dis. 2023 Feb 9;10(3):ofad073. doi: 10.1093/ofid/ofad073. eCollection 2023 Mar.

SARS-CoV-2 Vaccine-Induced T-Cell Response after Three Doses in People Living with HIV on Antiretroviral Therapy Compared to Seronegative Controls (CTN 328 COVAXHIV Study). Alexandrova Y, Yero A, Mboumba Bouassa RS, Comeau E, Samarani S, Brumme ZL, Hull M, Crawley AM, Langlois MA, Angel JB, Cooper CL, Needham J, Lee T, Singer J, Anis AH, Costiniuk CT, Jenabian MA. Viruses. 2023 Feb 19;15(2):575. doi: 10.3390/v15020575.

SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy. Cheung PK, Lapointe HR, Sang Y, Ennis S, Mwimanzi F, Speckmaier S, Barad E, Dong W, Liang R, Simons J, Lowe CF, Romney MG, Brumme CJ, Niikura M, Brockman MA, Brumme ZL; and the COVID-19 vaccine immunity study team. AIDS. 2023 Apr 1;37(5):F11-F18. doi: 10.1097/QAD.0000000000003519. Epub 2023 Feb 14.

Molecular Epidemiology of HIV-1 in Ghana: Subtype Distribution, Drug Resistance and Coreceptor Usage. Appah A, Beelen CJ, Kirkby D, Dong W, Shahid A, Foley B, Mensah M, Ganu V, Puplampu P, Amoah LE, Nii-Trebi NI, Brumme CJ, Brumme ZL. Viruses. 2022 Dec 31;15(1):128. doi: 10.3390/v15010128.

Inhibition of the TRIM24 bromodomain reactivates latent HIV-1. Horvath RM, Brumme ZL, Sadowski I. Sci Rep. 2023 Jan 11;13(1):556. doi: 10.1038/s41598-023-27765-3.

Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy. Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, Barad E, Moran-Garcia N, Datwani S, Duncan MC, Kalikawe R, Ennis S, Young L, Ganase B, Omondi FH, Umviligihozo G, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. AIDS. 2023 Apr 1;37(5):709-721. doi: 10.1097/QAD.0000000000003469. Epub 2022 Dec 22.

COVID-19 vaccine immunogenicity in people with HIV. Costiniuk CT, Singer J, Lee T, Langlois MA, Arnold C, Galipeau Y, Needham J, Kulic I, Jenabian MA, Burchell AN, Shamji H, Chambers C, Walmsley S, Ostrowski M, Kovacs C, Tan DHS, Harris M, Hull M, Brumme ZL, Lapointe HR, Brockman MA, Margolese S, Mandarino E, Samarani S, Vulesevic B, Lebouché B, Angel JB, Routy JP, Cooper CL, Anis AH; COVAXHIV Study Group. AIDS. 2023 Jan 1;37(1):F1-F10. doi: 10.1097/QAD.0000000000003429. Epub 2022 Nov 18.

HIV proviral genetic diversity, compartmentalization and inferred dynamics in lung and blood during long-term suppressive antiretroviral therapy. Shahid A, Jones BR, Yang JSW, Dong W, Shaipanich T, Donohoe K, Brumme CJ, Joy JB, Leung JM, Brumme ZL. PLoS Pathog. 2022 Nov 4;18(11):e1010613. doi: 10.1371/journal.ppat.1010613. eCollection 2022 Nov.

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8⁺ T cell immunity.  Rosás-Umbert M, Gunst JD, Pahus MH, Olesen R, Schleimann M, Denton PW, Ramos V, Ward A, Kinloch NN, Copertino DC, Escribà T, Llano A, Brumme ZL, Brad Jones R, Mothe B, Brander C, Fox J, Nussenzweig MC, Fidler S, Caskey M, Tolstrup M, Søgaard OS. Nat Commun. 2022 Oct 29;13(1):6473. doi: 10.1038/s41467-022-34171-2.

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Gunst JD, Pahus MH, Rosás-Umbert M, Lu IN, Benfield T, Nielsen H, Johansen IS, Mohey R, Østergaard L, Klastrup V, Khan M, Schleimann MH, Olesen R, Støvring H, Denton PW, Kinloch NN, Copertino DC, Ward AR, Alberto WDC, Nielsen SD, Puertas MC, Ramos V, Reeves JD, Petropoulos CJ, Martinez-Picado J, Brumme ZL, Jones RB, Fox J, Tolstrup M, Nussenzweig MC, Caskey M, Fidler S, Søgaard OS. Nat Med. 2022 Nov;28(11):2424-2435. doi: 10.1038/s41591-022-02023-7. Epub 2022 Oct 17.

Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccination.  Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Kalikawe R, Datwani S, Waterworth R, Umviligihozo G, Ennis S, Young L, Dong W, Kirkby D, Burns L, Leung V, Holmes DT, DeMarco ML, Simons J, Matic N, Montaner JSG, Brumme CJ, Prystajecky N, Niikura M, Lowe CF, Romney MG, Brockman MA, Brumme ZL. Front Immunol. 2022 Sep 6;13:947021. doi: 10.3389/fimmu.2022.947021. eCollection 2022.

SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8⁺ T-cells. Stevenson EM, Terry S, Copertino D, Leyre L, Danesh A, Weiler J, Ward AR, Khadka P, McNeil E, Bernard K, Miller IG, Ellsworth GB, Johnston CD, Finkelsztein EJ, Zumbo P, Betel D, Dündar F, Duncan MC, Lapointe HR, Speckmaier S, Moran-Garcia N, Papa MP, Nicholes S, Stover CJ, Lynch RM, Caskey M, Gaebler C, Chun TW, Bosque A, Wilkin TJ, Lee GQ, Brumme ZL, Jones RB. Nat Commun. 2022 Aug 19;13(1):4888. doi: 10.1038/s41467-022-32376-z.

Attenuated HIV-1 Nef But Not Vpu Function in a Cohort of Rwandan Long-Term Survivors. Umviligihozo G, Mann JK, Jin SW, Mwimanzi FM, Hsieh HA, Sudderuddin H, Lee GQ, Byakwaga H, Muzoora C, Hunt PW, Martin JN, Haberer JE, Karita E, Allen S, Hunter E, Brumme ZL, Brockman MA. Front Virol. 2022 Jun;2:917902. doi: 10.3389/fviro.2022.917902. Epub 2022 Jun 16.

People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses.  Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Speckmaier S, Moran-Garcia N, Datwani S, Duncan MC, Agafitei O, Ennis S, Young L, Ali H, Ganase B, Omondi FH, Dong W, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes DT, DeMarco ML, Simons J, Hedgcock M, Prystajecky N, Lowe CF, Pantophlet R, Romney MG, Barrios R, Guillemi S, Brumme CJ, Montaner JSG, Hull M, Harris M, Niikura M, Brockman MA, Brumme ZL. J Infect Dis. 2023 Apr 12;227(7):838-849. doi: 10.1093/infdis/jiac229.

Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, Kalikawe R, Datwani S, Omondi FH, Burns L, Young L, Leung V, Agafitei O, Ennis S, Dong W, Basra S, Lim LY, Ng K, Pantophlet R, Brumme CJ, Montaner JSG, Prystajecky N, Lowe CF, DeMarco ML, Holmes DT, Simons J, Niikura M, Romney MG, Brumme ZL, Brockman MA. J Infect Dis. 2022 Sep 21;226(6):983-994. doi: 10.1093/infdis/jiac199.

HAMdetector: a Bayesian regression model that integrates information to detect HLA-associated mutations.  Habermann D, Kharimzadeh H, Walker A, Li Y, Yang R, Kaiser R, Brumme ZL, Timm J, Roggendorf M, Hoffmann D. Bioinformatics. 2022 Apr 28;38(9):2428-2436. doi: 10.1093/bioinformatics/btac134.

Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC, Yaseen F, Agafitei O, Ennis S, Ng K, Basra S, Lim LY, Kalikawe R, Speckmaier S, Moran-Garcia N, Young L, Ali H, Ganase B, Umviligihozo G, Omondi FH, Atkinson K, Sudderuddin H, Toy J, Sereda P, Burns L, Costiniuk CT, Cooper C, Anis AH, Leung V, Holmes D, DeMarco ML, Simons J, Hedgcock M, Romney MG, Barrios R, Guillemi S, Brumme CJ, Pantophlet R, Montaner JSG, Niikura M, Harris M, Hull M, Brockman MA. NPJ Vaccines. 2022 Feb 28;7(1):28. doi: 10.1038/s41541-022-00452-6.

The Thiazole-5-Carboxamide GPS491 Inhibits HIV-1, Adenovirus, and Coronavirus Replication by Altering RNA Processing/Accumulation. Dahal S, Cheng R, Cheung PK, Been T, Malty R, Geng M, Manianis S, Shkreta L, Jahanshahi S, Toutant J, Chan R, Park S, Brockman MA, Babu M, Mubareka S, Mossman K, Banerjee A, Gray-Owen S, Brown M, Houry WA, Chabot B, Grierson D, Cochrane A. Viruses. 2021 Dec 30;14(1):60. doi: 10.3390/v14010060.

Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study. Cheung PK, Shahid A, Dong W, Lepik KJ, Montaner JSG, Brockman MA, Brumme ZL, Brumme CJ. J Antimicrob Chemother. 2022 Mar 31;77(4):979-988. doi: 10.1093/jac/dkab498.

CTN 328: immunogenicity outcomes in people living with HIV in Canada following vaccination for COVID-19 (HIV-COV): protocol for an observational cohort study. Costiniuk CT, Singer J, Langlois MA, Kulic I, Needham J, Burchell A, Jenabian MA, Walmsley S, Ostrowski M, Kovacs C, Tan D, Harris M, Hull M, Brumme Z, Brockman M, Margolese S, Mandarino E, Angel JB, Routy JP, Anis AH, Cooper C. BMJ Open. 2021 Dec 16;11(12):e054208. doi: 10.1136/bmjopen-2021-054208.

Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older Adults. Brockman MA, Mwimanzi F, Lapointe HR, Sang Y, Agafitei O, Cheung PK, Ennis S, Ng K, Basra S, Lim LY, Yaseen F, Young L, Umviligihozo G, Omondi FH, Kalikawe R, Burns L, Brumme CJ, Leung V, Montaner JSG, Holmes D, DeMarco ML, Simons J, Pantophlet R, Niikura M, Romney MG, Brumme ZL. J Infect Dis. 2022 Apr 1;225(7):1129-1140. doi: 10.1093/infdis/jiab592.

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. Deeks SG, Archin N, Cannon P, Collins S, Jones RB, de Jong MAWP, Lambotte O, Lamplough R, Ndung'u T, Sugarman J, Tiemessen CT, Vandekerckhove L, Lewin SR; International AIDS Society (IAS) Global Scientific Strategy working group. Nat Med. 2021 Dec;27(12):2085-2098. doi: 10.1038/s41591-021-01590-5. Epub 2021 Dec 1.

2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing. Zamiri M, Cheung PK, Brockman MA, Brumme ZL, Chabot B, Cochrane A, Grierson DS. ACS Med Chem Lett. 2021 Oct 29;12(11):1818-1823. doi: 10.1021/acsmedchemlett.1c00428. eCollection 2021 Nov 11.

HIV Proviral Burden, Genetic Diversity, and Dynamics in Viremic Controllers Who Subsequently Initiated Suppressive Antiretroviral Therapy. Omondi FH, Sudderuddin H, Shahid A, Kinloch NN, Jones BR, Miller RL, Tsai O, MacMillan D, Trocha A, Brockman MA, Brumme CJ, Joy JB, Liang R, Walker BD, Brumme ZL. mBio. 2021 Dec 21;12(6):e0249021. doi: 10.1128/mBio.02490-21. Epub 2021 Nov 16.

Concordance of HIV transmission risk factors elucidated using viral diversification rate and phylogenetic clustering. McLaughlin A, Sereda P, Brumme CJ, Brumme ZL, Barrios R, Montaner JSG, Joy JB. Evol Med Public Health. 2021 Sep 23;9(1):338-348. doi: 10.1093/emph/eoab028. eCollection 2021.

Proviral Turnover During Untreated HIV Infection Is Dynamic and Variable Between Hosts, Impacting Reservoir Composition on ART. Brooks K, Omondi FH, Liang RH, Sudderuddin H, Jones BR, Joy JB, Brumme CJ, Hunter E, Brumme ZL. Front Microbiol. 2021 Aug 19;12:719153. doi: 10.3389/fmicb.2021.719153. eCollection 2021.

SARS-CoV-2 RNA Quantification Using Droplet Digital RT-PCR. Kinloch NN, Ritchie G, Dong W, Cobarrubias KD, Sudderuddin H, Lawson T, Matic N, Montaner JSG, Leung V, Romney MG, Lowe CF, Brumme CJ, Brumme ZL. J Mol Diagn. 2021 Aug;23(8):907-919. doi: 10.1016/j.jmoldx.2021.04.014. Epub 2021 May 29.

A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. McCann CD, van Dorp CH, Danesh A, Ward AR, Dilling TR, Mota TM, Zale E, Stevenson EM, Patel S, Brumme CJ, Dong W, Jones DS, Andresen TL, Walker BD, Brumme ZL, Bollard CM, Perelson AS, Irvine DJ, Jones RB. J Exp Med. 2021 Jul 5;218(7):e20201908. doi: 10.1084/jem.20201908. Epub 2021 May 14.

Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada.  Matic N, Lowe CF, Ritchie G, Stefanovic A, Lawson T, Jang W, Young M, Dong W, Brumme ZL, Brumme CJ, Leung V, Romney MG. Emerg Infect Dis. 2021 Jun;27(6):1673-1676. doi: 10.3201/eid2706.210532. Epub 2021 Mar 30.

Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. McCluskey SM, Kamelian K, Musinguzi N, Kigozi S, Boum Y 2nd, Bwana MB, Muzoora C, Brumme ZL, Carrington M, Carlson J, Foley B, Hunt PW, Martin JN, Bangsberg DR, Harrigan PR, Siedner MJ, Haberer JE, Lee GQ. AIDS. 2021 Jun 1;35(7):1083-1089. doi: 10.1097/QAD.0000000000002854.

HLA-E-restricted HIV-1-specific CD8+ T cell responses in natural infection. Bansal A, Gehre MN, Qin K, Sterrett S, Ali A, Dang Y, Abraham S, Costanzo MC, Venegas LA, Tang J, Manjunath N, Brockman MA, Yang OO, Kan-Mitchell J, Goepfert PA. J Clin Invest. 2021 Aug 16;131(16):e148979. doi: 10.1172/JCI148979.

Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency. Schonhofer C, Yi J, Sciorillo A, Andrae-Marobela K, Cochrane A, Harris M, Brumme ZL, Brockman MA, Mounzer K, Hart C, Gyampoh K, Yuan Z, Montaner LJ, Tietjen I. Biochem Pharmacol. 2021 Apr;186:114462. doi: 10.1016/j.bcp.2021.114462. Epub 2021 Feb 10.

HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Kinloch NN, Ren Y, Conce Alberto WD, Dong W, Khadka P, Huang SH, Mota TM, Wilson A, Shahid A, Kirkby D, Harris M, Kovacs C, Benko E, Ostrowski MA, Del Rio Estrada PM, Wimpelberg A, Cannon C, Hardy WD, MacLaren L, Goldstein H, Brumme CJ, Lee GQ, Lynch RM, Brumme ZL, Jones RB. Nat Commun. 2021 Jan 8;12(1):165. doi: 10.1038/s41467-020-20442-3.